Navigation Links
Genzyme Reports Strong Second-Quarter Growth
Date:7/23/2008

icipated global demand for Myozyme. Product supply in 2009 is expected to be particularly tight until the Belgium plant is approved.

Genzyme's other treatments for lysosomal storage disorders also continue to experience strong, double-digit growth. Second-quarter Cerezyme(R) (imiglucerase for injection) sales rose 13 percent to $319.4 million, compared with $283.0 million in the previous second quarter. Sales of Fabrazyme(R) (agalsidase beta) grew 21 percent, rising to $126.6 million from $104.3 million. Sales of Aldurazyme(R) (laronidase) increased 33 percent to $38.8 million, compared with $29.1 million in the second quarter last year when the product's sales were recorded under the joint venture with BioMarin Pharmaceutical Inc.

The company also reported preliminary results from a Phase 2 trial of its investigational oral therapy for Gaucher disease Genz-112638. The results were consistent with those observed for patients beginning enzyme replacement therapy, and they highlight the potential of this compound to provide a convenient treatment alternative for patients and a broader range of treatment options for physicians. Genzyme is developing protocols for two Phase 3 trials that it expects to initiate early next year.

Sales of Thyrogen(R) (thyrotropin alfa for injection) remained strong, increasing 34 percent to $39.4 million from $29.5 million. The use of Thyrogen in ablation procedures is contributing to the product's growth in the United States, while its growth in Europe is being driven by increasing diagnosis of thyroid cancer and its international adoption is being driven by expansion into new geographic markets.

Within the Renal business, sales of sevelamer therapies Renagel(R) (sevelamer hydrochloride) and Renvela grew 16 percent to $168.6 million from $144.9 million in the second quarter last year. Genzyme launched Renvela in the United States in March, and the product is now included in more than 85 percent of health plan f
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... The Latin American hardware encryption display market report defines ... and forecast of revenue. This market was valued at ... $2,366.8 million by 2018, at a CAGR of 70.3% ... of the Latin American hardware encryption market report to ... also provides a glimpse of the segmentation of the ...
(Date:10/19/2014)... The Asian Automatic patient billing report ... and forecast of revenue. The Automatic patient billing market ... million by 2018, at a developing CAGR of 7.2% ... of the Asian Automatic patient billing market, to get ... provides a glimpse of the segmentation of this market ...
(Date:10/19/2014)... 2014 The report "Unmanned Ground ... Security), Technology, Payload, Type & by Geography - ... global unmanned ground vehicle market into various sub ... market sizes. The report also identifies the factors ... it along with the adoption trends. , The ...
(Date:10/18/2014)... The report "1,6-Hexanediol Market by Application ... 2019", analyzes the global market on the basis ... industry details such as the key drivers, current ... , Browse 81 Market Data Tables and 29 ... on “1,6-Hexanediol Market by Application and by Geography ...
Breaking Biology Technology:The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 2Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 3Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 51,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 21,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 31,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 5
... The following statement was issued today by the law firm of Barroway ... Notice is hereby given that a class action lawsuit was filed ... York on behalf of purchasers of the securities of Elan Corporation, plc ... 2007 and October 21, 2008, inclusive (the "Class Period"). , ...
... Dec. 11 Myngle,( http://www.myngle.com ), the global ... ICT company at the Europe Unlimited,s European Venture ... EVS is a showcase for ... and new energy entrepreneurs from all over Europe ...
... and ST. PAUL, Minn., Dec. 11 The University ... research from the,Richard M. Schulze Family Foundation. Goals for ... on the University,s strength in diabetes,research and to accelerate the ... type 1 diabetes. , ...
Cached Biology Technology:Shareholder Class Action Filed Against Elan Corporation, plc by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP 2Myngle Best ICT Company at the European Ventures Summit 2University of Minnesota Receives $40 Million for Type 1 Diabetes Research 2University of Minnesota Receives $40 Million for Type 1 Diabetes Research 3University of Minnesota Receives $40 Million for Type 1 Diabetes Research 4
(Date:10/16/2014)... be cultivated efficiently, they are anything but sustainable: ... monoculture cultivation is becoming increasingly evident. Despite their ... and are regarded as the sole possibility of ... wrongfully, finds Bernhard Schmid, an ecology professor at ... form of agriculture and forestry. After all, a ...
(Date:10/15/2014)... our ability to assess the pandemic risk from strains ... we must not allow ourselves to become complacent that ... international consortium of scientists. , Influenza pandemics arise when ... yet to develop widespread immunity – spreads in the ... the past 100 years, the worst of which – ...
(Date:10/15/2014)... , Oct. 15, 2014 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market releases photos and ... Times Square on Monday October 13 th . ... David Tunnel and angel investor Mr. Chad A. Verdi ... CEO of NXT-ID thanked his investors and employees "for their work ...
Breaking Biology News(10 mins):Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3
... they get rid of excess energy through the production of hydrogen. ... notice the absence of oxygen. For this, they need the messenger ... from red blood cells of humans. With colleagues at the UC ... ". Haemoglobin an old protein in a new ...
... human genome more readily in tumors than in normal ... University of Maryland School of Medicine,s Institute for Genome ... Human Genome Project, the 1,000 Genomes Project and The ... lateral gene transfer (LGT), the transmission of genetic material ...
... of the esteemed Cubist-ICAAC Award is George L. ... University of Florida, for his application of pharmacokinetic ... development. According to his nominator, Michael Dudley, Rempex ... work using pharmacokinetics/pharmacodynamics to simulate and then validate ...
Cached Biology News:When green algae run out of air 2Bacterial DNA may integrate into human genome more readily in tumor tissue 2The American Society for Microbiology honors George L. Drusano 2
XBP1 Antibody...
Recombinant Mouse MMP-9, CF...
Phosphorylcholine hapten is conjugated to BSA protein by use of p-diazonium phenylphosphorylcholine....
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
Biology Products: